FDA Approves J&J’s NaviStar ThermoCool For Atrial Fibrillation Ablation
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J/Biosense Webster’s first-to-market status likely to last several years while Medtronic, Boston Scientific, St. Jude Medical and CardioFocus seek approval in the indication for their cardiac ablation catheters.
You may also be interested in...
Medtronic Makes Another Big Play In A-Fib, Purchases Ablation Frontiers
Medtronic will add anatomically designed radiofrequency ablation catheters for treatment of atrial fibrillation to its fledgling AF Solutions division through the purchase of privately held Ablation Frontiers
FDA Panel Success Puts ThermoCool First In Line For AF Ablation Indication
Johnson & Johnson/Biosense Webster's Navistar ThermoCool saline irrigated radio-frequency ablation catheterhas the inside track to become the first ablation catheter with an FDA-approved indication for atrial fibrillation following a unanimous recommendation from the agency's Circulatory System Devices Panel
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.